Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

PURPOSE: Ribociclib has provided significant improvements in progression-free survival (PFS) and overall survival (OS) of postmenopausal patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC). However, given the high cos...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Manag Res
Päätekijät: Yang, Jiangping, Han, Jiaqi, Tian, Maolang, Tian, Kun, Liao, Wenjun, Yan, Xi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Dove 2020
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7751309/
https://ncbi.nlm.nih.gov/pubmed/33364838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S284556
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia